Survival results for 103 patients who had an available assessment of hematologic response (including bone marrow response) at 2 months.

Of the 16 patients with a CHR or marrow response, 11 (69%) are still alive, compared with 16 (40%) of the 40 patients with an RTC (median survival, 11.7 months) and only 5 (11%) of the 47 patients with no documented response at 2 months (median survival, 6.1 months;P < .001 on log rank test).